Roger Adsett

Roger joined Insmed in September of 2016 as Chief Commercial Officer, and in November 2019 was appointed Chief Operating Officer. Prior to Insmed, Roger held various leadership roles with Shire from 2005 to 2016. During his time as senior vice president of its gastrointestinal and internal medicine business unit, Roger oversaw global commercial P&L across six specialty and two rare disease brands within his BU. Previously, he served as Shire’s gastrointestinal business unit leader, responsible for building a leading GI specialty business. Before Shire, Roger worked at AstraZeneca for 11 years in a variety of commercial positions, including marketing director for the US launch of Nexium®, a medicine for the treatment of gastroesophageal reflux disease (GERD), and the global brand director for Symbicort®, a medicine for the treatment of asthma and chronic obstructive pulmonary disease. Prior to AstraZeneca, Roger spent three years at Accenture. Roger holds a Master of Business Administration from The Wharton School at the University of Pennsylvania and a Bachelor of Arts in English and Economics from Bucknell University. He is a member of the board of directors of Landos Biopharma, Inc. (NASDAQ: LABP).